Today I start a clinical trial for ARV-766, an AR degrader. I'm coming in at phase 2, and they are only accepting men who have one of 4 point mutations in the AR - I have two. I've been randomized to 300 mg pill, once a day. The other dose is 100mg.
I've failed ADT, chemo. Keytruda & Pluvicto. Hoping #5 will be the one. Here's more info: ir.arvinas.com/news-release...
I wish you good results!
i see you had genetics done: is the MMR-d germline which caused the MSH-h in tumor?
Your bio: “Genomic testing showed MMR-d and MSI-h with TMB high”
ncbi.nlm.nih.gov/pmc/articl...
May 2023 article.
Recent Research Advances in Double-Strand Break and Mismatch Repair Defects in Prostate Cancer and Potential Clinical Applications
In this review, we have summarized recent studies focused on two of the DDR pathways, MMR and DSBR, in PC and their implications for cancer therapy, particularly in regard to prostate cancer. The aim is to provide a comprehensive overview of the current state of the field and to highlight areas for future research and development.
is this the trial
clinicaltrials.gov/study/NC...
It good and interesting that it is an oral drug.
cancer.gov/publications/dic...
androgen receptor degrader ARV-766
An orally bioavailable androgen receptor (AR)-targeted protein degrader, composed of an AR ligand attached to an E3 ligase recognition moiety and utilizing the proteolysis targeting chimera (PROTAC) technology, with potential antineoplastic activity. Upon oral administration, AR degrader ARV-766 targets and binds to the AR ligand binding domain on the AR. E3 ligase is then recruited to the AR by the E3 ligase recognition moiety of ARV-766 and the AR is tagged by ubiquitin. This causes ubiquitination and degradation of AR by the proteasome, and prevents the expression of AR target genes and halts AR-mediated signaling. This inhibits the proliferation of AR-overexpressing tumor cells. In addition, the degradation of the AR releases ARV-766, allowing it to bind to additional AR. AR plays a key role in the proliferation of castration-resistant prostate cancer cells (CRPC). ARV-766 may degrade resistance-driving point mutations of AR, including the L702H mutation associated with treatments including abiraterone.
Good luck! Let us know how it goes.
Good luck 
Please share side effects
they are very advanced in their research…I hope you will be an outstanding responder!! Good luck! 🙏🙏💪💪
Wishing you a great response. Good luck!
Good luck! I hope it works well for you.
Good luck! Please, keep us posted how it goes.
Good luck!!!
Hoping fantastic results for your clinical trial and for playing the Lotto....
Good Luck, Good Health and Good Humor.
j-o-h-n
To get this straight, the drug is to make ADT and something like Abi work again? Do you keep taking them during the trial? Or is this a stand alone?
Best of luck to you
An update, after 2 weeks on ARV-766, my PSA is down 50% (133 to 66)! My bone pain is lessened and no side effects, so far.
great!! Keep posting please, it’s good to have a report from a direct experience
God bless You
Three clinical trial options after Zytiga fails
Starting a trial on Thursday.
Clinical Trial Starts Today
Question about availability of Lu-177 therapy
